Citizens JMP raised the firm’s price target on Terns Pharmaceuticals (TERN) to $35 from $25 and keeps an Outperform rating on the shares. Terns’s ASH abstract showed that TERN-701 delivered an unprecedented 24-week major molecular response rate in 2L+ relapsed/refractory chronic myeloid leukemia, outperforming other Phase 1 CML therapies in efficacy and tolerability, the analyst tells investors in a research note. Feedback from key opinion leaders suggests the drug is on a best-in-class trajectory with real potential to move into the front-line setting, the firm says.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals price target raised to $36 from $28 at Barclays
- Promising Outlook for TERN-701 in CML Market: Buy Rating Affirmed by Analyst
- Terns Pharmaceuticals price target raised to $35 from $28 at Truist
- Terns Pharmaceuticals price target raised to $30 from $22 at BMO Capital
- Terns Pharmaceuticals: Promising Clinical Results and Strong Financial Position Justify Buy Rating